UBS Group’s Candel Therapeutics CADL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $416K | Sell |
82,167
-104,927
| -56% | -$531K | ﹤0.01% | 4978 |
|
|
2025
Q1 | $1.06M | Buy |
187,094
+30,288
| +19% | +$171K | ﹤0.01% | 4161 |
|
|
2024
Q4 | $1.36M | Buy |
156,806
+147,360
| +1,560% | +$1.28M | ﹤0.01% | 4015 |
|
|
2024
Q3 | $65.5K | Buy |
9,446
+3,441
| +57% | +$23.8K | ﹤0.01% | 5454 |
|
|
2024
Q2 | $37.2K | Buy |
6,005
+5,995
| +59,950% | +$37.2K | ﹤0.01% | 5763 |
|
|
2024
Q1 | $16 | Sell |
10
-11,911
| -100% | -$19.1K | ﹤0.01% | 7883 |
|
|
2023
Q4 | $17.5K | Buy |
11,921
+11,911
| +119,110% | +$17.5K | ﹤0.01% | 5978 |
|
|
2023
Q3 | $9 | Hold |
10
| – | – | ﹤0.01% | 8078 |
|
|
2023
Q2 | $13 | Hold |
10
| – | – | ﹤0.01% | 7632 |
|
|
2023
Q1 | $14 | Sell |
10
-785
| -99% | -$1.1K | ﹤0.01% | 8342 |
|
|
2022
Q4 | $1.42K | Sell |
795
-3,386
| -81% | -$6.06K | ﹤0.01% | 8674 |
|
|
2022
Q3 | $13K | Buy |
4,181
+374
| +10% | +$1.16K | ﹤0.01% | 6909 |
|
|
2022
Q2 | $12K | Buy |
3,807
+1,807
| +90% | +$5.7K | ﹤0.01% | 6599 |
|
|
2022
Q1 | $10K | Sell |
2,000
-2,447
| -55% | -$12.2K | ﹤0.01% | 7342 |
|
|
2021
Q4 | $34K | Buy |
4,447
+1,447
| +48% | +$11.1K | ﹤0.01% | 6149 |
|
|
2021
Q3 | $33K | Buy |
+3,000
| New | +$33K | ﹤0.01% | 5543 |
|